BCM
CABA icon

Boone Capital Management’s Cabaletta Bio CABA Stock Holding History

Boone Capital Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-266,882
Closed -$2.47M – 15
2022
Q4 		$2.47M Buy
+266,882
New +$972K 1.27% 16

Other funds holding CABA

FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Boone Capital Management's CABA Position: Q1 2023 in Review

Boone Capital Management sold out of Cabaletta Bio (CABA) in Q1 2023, closing a stake of 266,882 shares — an estimated $2.47M sold.

Boone Capital Management first reported a position in CABA in Q4 2022 and held it in 1 quarter. The position peaked at $2.47M in Q4 2022. 71 funds tracked by Wall St. Rank hold CABA as of Q1 2023.

  • Boone Capital Management reported no remaining Cabaletta Bio position as of Q1 2023 after selling out during the quarter.
  • Boone Capital Management sold 266,882 Cabaletta Bio shares in Q1 2023, an estimated $2.47M.
  • Boone Capital Management first reported a position in Cabaletta Bio in Q4 2022 and held it in 1 quarter.
  • Boone Capital Management's Cabaletta Bio position peaked at $2.47M in Q4 2022.
  • 71 funds tracked by Wall St. Rank held Cabaletta Bio as of Q1 2023.

Based on Boone Capital Management's 13F filing for Q1 2023, filed 15 May 2023.